AxoGen (NASDAQ:AXGN – Get Rating) announced its quarterly earnings results on Wednesday. The medical equipment provider reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.05), MarketWatch Earnings reports. AxoGen had a negative net margin of 24.98% and a negative return on equity of 25.97%. During the same period in the previous year, the firm posted ($0.15) earnings per share.
Shares of AXGN traded down $0.74 on Friday, hitting $9.03. 552,228 shares of the stock traded hands, compared to its average volume of 284,794. The company has a quick ratio of 4.54, a current ratio of 5.23 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $379.08 million, a P/E ratio of -11.88 and a beta of 0.75. The stock’s 50 day moving average is $8.07 and its two-hundred day moving average is $9.44. AxoGen has a 1 year low of $6.87 and a 1 year high of $23.94.
AXGN has been the subject of a number of research analyst reports. Canaccord Genuity Group dropped their price target on AxoGen from $15.00 to $12.00 and set a “hold” rating for the company in a research report on Wednesday, February 23rd. StockNews.com initiated coverage on AxoGen in a research report on Thursday, March 31st. They issued a “hold” rating for the company. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $20.75.
About AxoGen (Get Rating)
AxoGen, Inc, together with its subsidiaries, develops and markets surgical solutions for physical damage or transection to peripheral nerves. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.
- Get a free copy of the StockNews.com research report on AxoGen (AXGN)
- Three Stocks To Ride Out A Rough Market
- MarketBeat: Week in Review 5/2 – 5/6
- AMD (NASDAQ: AMD) Shines Green In A Sea Of Red
- Expedia or Bookings Holdings: Which Stock Should You Travel With?
- Is This The Bottom For Papa John’s International?
Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.